X0202 SCHEDULE 13G/A 0001930214 XXXXXXXX LIVE 1 Common Stock, $0.0001 par value per share 06/30/2026 0000034956 Tenax Therapeutics, Inc. 88032L605 101 Glen Lennox Drive Suite 300 Chapel Hill NC 27517 Rule 13d-1(c) Vivo Opportunity Fund Holdings, L.P. b DE 3458327.00 0.00 3458327.00 0.00 3458327.00 N 9.0 PN The number represents 2,500,000 shares of common stock, par value $0.0001 per share (the "Common Stock") of Tenax Therapeutics, Inc. (the "Issuer"), and pre-funded warrants to purchase 958,327 shares of the Issuer's Common Stock (the "Pre-Funded Warrants"). All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percentage of class is based on 37,423,917 shares of Common Stock outstanding, as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on July 31, 2026, plus 958,327 shares of the Issuer's Common Stock issuable upon the exercise of the Pre-Funded Warrants. Vivo Opportunity, LLC b DE 3458327.00 0.00 3458327.00 0.00 3458327.00 N 9.0 OO The number represents 2,500,000 shares of Common Stock of the Issuer, and Pre-Funded Warrants to purchase 958,327 shares of the Issuer's Common Stock. All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The percent of class was based on 37,423,917 shares of Common Stock of the Issuer outstanding as of July 28, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the SEC on July 31, 2026, plus 958,327 shares of the Issuer's Common Stock issuable upon the exercise of the Pre-Funded Warrants. Tenax Therapeutics, Inc. 101 Glen Lennox Drive, Suite 300, Chapel Hill, North Carolina, 27517 (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. The address of the principal business office of the Reporting Persons is 192 Lytton Avenue, Palo Alto, CA 94301. (i) Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership; and (ii) Vivo Opportunity, LLC, a Delaware limited liability company. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Y The shares reported in this Schedule 13G include 2,500,000 shares of Common Stock of the Issuer, and pre-funded warrants to purchase 958,327 shares of the Issuer's Common Stock (the "Pre-Funded Warrants"). All securities are held of record by Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity, LLC is the general partner of Vivo Opportunity Fund Holdings, L.P. Vivo Opportunity Fund Holdings, L.P. 9.0% Vivo Opportunity, LLC 9.0%* Vivo Opportunity Fund Holdings, L.P. 3,458,327 Vivo Opportunity, LLC 3,458,327 Vivo Opportunity Fund Holdings, L.P. 0 Vivo Opportunity, LLC 0 Vivo Opportunity Fund Holdings, L.P. 3,458,327 Vivo Opportunity, LLC 3,458,327 Vivo Opportunity Fund Holdings, L.P. 0 Vivo Opportunity, LLC 0 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. Vivo Opportunity Fund Holdings, L.P. /s/ Kevin Dai 08/14/2026 Vivo Opportunity, LLC /s/ Kevin Dai 08/14/2026